Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin + Carvedilol vs. Carvedilol Alone for Patients With Cirrhosis and Left Ventricular Diastolic Dysfunction and Impact on Hepatic Decompensation and Survival: A Double-Blind Placebo-Controlled Randomized Controlled Trial

NCT07322237 is registered in ClinicalTrials.gov with Post Graduate Institute of Medical Education and Research, Chandigarh as lead sponsor.

NCT NCT07322237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07322237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin + Carvedilol vs. Carvedilol Alone for Patients With Cirrhosis and Left Ventricular Diastolic Dysfunction and Impact on Hepatic Decompensation and Survival: A Double-Blind Placebo-Controlled Randomized Controlled Trial
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase
Phase 4
Overall status
Recruiting
Start date
April 1, 2026
Completion date
June 30, 2029
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiometabolic risk factors, cirrhosis, cirrhotic cardiomyopathy, empagliflozin